Braveheart Bio (NASDAQ:BRVE) Upgraded at The Goldman Sachs Group

Braveheart Bio (NASDAQ:BRVE) was upgraded by analysts at The Goldman Sachs Group to a “strong-buy” rating in a note issued to investors on Monday, Zacks reports.

A number of other analysts have also weighed in on BRVE. Stifel Nicolaus assumed coverage on shares of Braveheart Bio in a report on Monday. They set a “buy” rating and a $45.00 target price on the stock. TD Cowen began coverage on shares of Braveheart Bio in a report on Monday. They issued a “buy” rating for the company. Jefferies Financial Group initiated coverage on shares of Braveheart Bio in a research report on Monday. They set a “buy” rating and a $48.00 price target for the company. Wall Street Zen raised shares of Braveheart Bio to a “hold” rating in a report on Saturday, August 15th. Finally, Cantor Fitzgerald assumed coverage on Braveheart Bio in a research note on Monday. They set an “overweight” rating and a $40.00 price objective for the company. Two research analysts have rated the stock with a Strong Buy rating and three have issued a Buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $45.25.

Braveheart Bio Price Performance

Shares of Braveheart Bio stock opened at $25.50 on Monday. Braveheart Bio has a 12-month low of $24.31 and a 12-month high of $32.00.

Insider Buying and Selling

In related news, major shareholder Growth Opportunities F. Forbion bought 1,920,000 shares of the company’s stock in a transaction on Friday, August 7th. The stock was acquired at an average cost of $18.00 per share, for a total transaction of $34,560,000.00. Following the completion of the transaction, the insider directly owned 11,640,546 shares in the company, valued at $209,529,828. This trade represents a 19.75% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Erez Chimovits purchased 1,940,000 shares of the business’s stock in a transaction on Friday, August 7th. The stock was bought at an average cost of $18.00 per share, with a total value of $34,920,000.00. Following the purchase, the director owned 11,901,826 shares in the company, valued at approximately $214,232,868. This represents a 19.47% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders purchased 8,751,942 shares of company stock valued at $157,534,956 in the last 90 days.

About Braveheart Bio

We are a clinical?stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB?1893, is a next-generation oral small?molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non?obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.